StockChartsAI.com
All Chart Prices Delayed at least 15 minutesBefore accessing this site, you agree that you have read and agree to the disclaimers at the bottom of this page.
Stock Charts AI Power Rank: 7.6
Power Rank trend -> Falling
03/27/2025 16:22:00 EST
Bristol-Myers Squibb Company (BMY)
Industry: Drug Manufacturers - General
Follow @stockchartsai on TwitterPrice Support Resistance
In the past 20 trading days, BMY has been trading in a range between $63.11 and $58.80 (gray range band). Red lines on the chart represent key resistance levels and Green lines represent key support levels. As the price moves above the lines you will notice they turn green and red if price moves below a line.
BMY is trading below resistance at $63.11, about 7% to the upside. There is support at $58.50 -1% to the downside. If it can break above the resistance, it could have some more upside. If the price starts to turn down and fails to get through this level or enters a yellow zone, we would consider profit taking or exiting the position. If it enters a red zone on the chart we would exit the position.
Upside / Downside Potential
Bristol-Myers Squibb Company $BMY entered a Green zone 22 days ago on the AI powered stock chart. Wall Street analysts have an AVG target price $61.0057, a potential upside of 3.03% from the recent price of 59.21. The stock is trading 6.96% (potential upside) below its 52 week high of $63.33 and 55.08 % (potential downside) above its 52 week low of $38.18 - based on the recent price.
Company Summary
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel to treat patients with Philadelphia chromosome-positive chronic myeloid leukemia.
News
| Trump Weighs Tariffs on Ireland's Pharma Industry. How to Play the Sector. Biopharmaceutical stocks are having their time in the spotlight thanks to President Donald Trump, who vowed to take aim at Ireland's status as a pharma hub with new tariffs. Analysts at Jefferies JEF-8.32% say there is a smart way to play the sector. Source: Market Watch Thu, 27 Mar 2025 10:22:00 -0400 Sentiment: Negative |
| 3 Deeply Discounted Dividend Stocks to Buy Today Want to buy a good dividend stock and secure a great price in the process? I have a list of three stocks that can help you diversify your portfolio, allow you to earn above-average dividends, and score some potential bargains in the process. Source: The Motley Fool Thu, 27 Mar 2025 08:17:00 -0400 Sentiment: Positive |
| Bristol Myers Squibb (BMY) Rises As Market Takes a Dip: Key Facts Bristol Myers Squibb (BMY) closed the most recent trading day at $59.21, moving +0.03% from the previous trading session. Source: Zacks Investment Research Wed, 26 Mar 2025 18:46:06 -0400 Sentiment: Neutral |
| Bristol-Myers Squibb's Rally Is Well Deserved, Albeit Warranting A Downgrade To Hold BMY has enjoyed robust capital appreciation over the past few months, significantly aided by the ongoing market rotation to value/ defensive stocks. This is significantly aided by the double beat FQ4'24 performance and the decent FY2025 guidance, as the management drives renewed growth through new portfolios and M&A activities. Despite the higher net debts on balance sheet, we believe that BMY's dividends remain safe as observed in the richer cash flows and recent payout raise. Source: Seeking Alpha Tue, 25 Mar 2025 10:22:33 -0400 Sentiment: Neutral |
| Bristol Myers Stock: This Covered Call Could Enhance Your Return Beyond A 4% Dividend Yield The sold call produces a 9.83% annualized yield in addition to the dividend. The post Bristol Myers Stock: This Covered Call Could Enhance Your Return Beyond A 4% Dividend Yield appeared first on Investor's Business Daily. Source: Investors Business Daily Mon, 24 Mar 2025 13:14:59 -0400 Sentiment: Positive |
Technicals 52 Week Hi: 63.33 52 Week Low: 38.1829 Beta: 0.436 50 Day MA: 58.445 200 Day MA: 52.6126 Earnings / Revenue Trends Qtr Earnings Growth YOY: -0.959 Qtr Revenue Growth YOY: 0.075 Forward PE: 8.7489 Trailing PE: 0